Core Viewpoint - Catalyst Pharmaceuticals has announced that Health Canada has accepted the New Drug Submission for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), which has been granted Priority Review, potentially leading to marketing authorization by the end of 2025 [1][2] Company Overview - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel medicines for rare diseases [1][7] - The company has a proven track record of bringing life-changing treatments to market and prioritizes patient accessibility through comprehensive support services [7] Product Information - AGAMREE is a 40 mg/mL oral suspension that received FDA approval on October 26, 2023, for treating DMD in patients aged two years and older, and became commercially available in the U.S. on March 13, 2024 [2] - AGAMREE's unique mechanism of action allows it to potentially provide comparable efficacy to standard corticosteroids while offering a better-tolerated side effect profile [4] - In the pivotal VISION-DMD study, AGAMREE met its primary endpoint with a statistically significant improvement in Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks [4] Market Context - Duchenne muscular dystrophy (DMD) is a genetic disorder that primarily affects males, leading to progressive muscle degeneration and weakness, with symptoms typically appearing in early childhood [3] - If approved, AGAMREE would be the first and only treatment option indicated for DMD patients in Canada, addressing a significant unmet medical need [1][2] Collaboration and Strategy - Catalyst collaborates with Kye Pharmaceuticals, its Canadian sub-licensee, to ensure access to AGAMREE for DMD patients, particularly in underserved communities [2][5] - Kye Pharmaceuticals is focused on bringing novel prescription medicines to the Canadian market, addressing clinically significant unmet needs across various therapeutic areas [5]